This database contains 67 studies, archived under the term: "magnetic resonance imaging"
Click here to filter this large number of results.
Donepezil treatment in Alzheimer’s disease patients with and without cerebrovascular lesions: a preliminary report
Na, Hae-Ri,
Kim, SangYun,
Choi, Seong Hye,
Yang, Dong-Won,
Bae, Hee-Joon,
Kim, Jung-Eun,
Park, Mee-Young,
Shim, Yong-Soo,
Kim, Byung-Kun,
Kwon, Jae-Cheol,
Yoo, Bong Goo,
Kim, Byeong-Chae,
Lee, Jung-Seok
Aim: Donepezil has not been evaluated in Korean patients with Alzheimer’s disease (AD) for up to 1 year. The objectives of this study were to evaluate the differential efficacy of donepezil in Korean AD patients with and without concomitant cerebrovascular lesions (CVL).; Methods: This study was a 48-week open-label trial of donepezil in patients with […]
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
Quinn, Joseph F.,
Raman, Rema,
Thomas, Ronald G.,
Yurko-Mauro, Karin,
Nelson, Edward B.,
van Dyck, Christopher,
Galvin, James E.,
Emond, Jennifer,
Jack, Clifford R., Jr.,
Weiner, Michael,
Shinto, Lynne,
Aisen, Paul S
Context: Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.; Objective: To determine if supplementation with DHA slows cognitive and functional decline […]
Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study
Coker, L. H.,
Hogan, P. E.,
Bryan, N. R.,
Kuller, L. H.,
Margolis, K. L.,
Bettermann, K.,
Wallace, R. B.,
Lao, Z.,
Freeman, R.,
Stefanick, M. L.,
Shumaker, S. A.
Objective: The Women’s Health Initiative Memory Study (WHIMS) hormone therapy (HT) trials reported that conjugated equine estrogen (CEE) with or without medroxyprogesterone acetate (MPA) increases risk for all-cause dementia and global cognitive decline. WHIMS MRI measured subclinical cerebrovascular disease as a possible mechanism to explain cognitive decline reported in WHIMS.; Methods: We contacted 2,345 women […]
Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer’s disease
Babiloni, Claudio,
Frisoni, Giovanni B.,
Del Percio, Claudio,
Zanetti, Orazio,
Bonomini, Cristina,
Cassetta, Emanuele,
Pasqualetti, Patrizio,
Miniussi, Carlo,
De Rosas, Mario,
Valenzano, Anna,
Cibelli, Giuseppe,
Eusebi, Fabrizio,
Rossini, Paolo M.
Objective: Non-steroidal anti-inflammatory drugs such as ibuprofen have a protective role on risk of Alzheimer’s disease (AD). Here we evaluated the hypothesis that long-term ibuprofen treatment affects cortical sources of resting electroencephalographic (EEG) rhythms in mild AD patients.; Methods: Twenty-three AD patients (13 treated AD IBUPROFEN; 10 untreated AD PLACEBO) were enrolled. Resting EEG data […]
A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease
Laxton, Adrian W.,
Tang-Wai, David F.,
McAndrews, Mary Pat,
Zumsteg, Dominik,
Wennberg, Richard,
Keren, Ron,
Wherrett, John,
Naglie, Gary,
Hamani, Clement,
Smith, Gwenn S.,
Lozano, Andres M.
Objective: Alzheimer disease (AD) is characterized by functional impairment in the neural elements and circuits underlying cognitive and memory functions. We hypothesized that fornix/hypothalamus deep brain stimulation (DBS) could modulate neurophysiological activity in these pathological circuits and possibly produce clinical benefits.; Methods: We conducted a phase I trial in 6 patients with mild AD receiving […]
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H.,
Doody, R. S.,
Kivipelto, M.,
Sparks, D. L.,
Waters, D. D.,
Jones, R. W.,
Schwam, E.,
Schindler, R.,
Hey-Hadavi, J.,
DeMicco, D. A.,
Breazna, A.
Background: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD.; Methods: This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to […]
Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy
Clare, Linda,
Linden, David E. J.,
Woods, Robert T,
Whitaker, Rhiannon,
Evans, Suzannah J.,
Parkinson, Caroline H.,
van Paasschen, Jorien,
Nelis, Sharon M.,
Hoare, Zoe,
Yuen, Kenneth S. L.,
Rugg, Michael D.
Objectives: To provide evidence regarding the clinical efficacy of cognitive rehabilitation (CR) in early-stage Alzheimer disease (AD).; Design: Single-blind randomized controlled trial comparing CR with relaxation therapy and no treatment.; Setting: Outpatient, community-based setting.; Participants: Sixty-nine individuals (41 women, 28 men; mean age 77.78 years, standard deviation 6.32, range = 56-89) with a diagnosis of […]
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative
Carmichael, Owen,
Schwarz, Christopher,
Drucker, David,
Fletcher, Evan,
Harvey, Danielle,
Beckett, Laurel,
Jack, Clifford R., Jr.,
Weiner, Michael,
DeCarli, Charles
Objective: To evaluate relationships between magnetic resonance imaging (MRI)-based measures of white matter hyperintensities (WMHs), measured at baseline and longitudinally, and 1-year cognitive decline using a large convenience sample in a clinical trial design with a relatively mild profile of cardiovascular risk factors.; Design: Convenience sample in a clinical trial design.; Subjects: A total of […]
A single ascending dose study of bapineuzumab in patients with Alzheimer disease
Black, Ronald S.,
Sperling, Reisa A.,
Safirstein, Beth,
Motter, Ruth N.,
Pallay, Allan,
Nichols, Alice,
Grundman, Michael
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. Thirty patients received bapineuzumab infusion of 0.5, 1.5, or 5 mg/kg or placebo (6 active, 2 placebo for 0.5 […]
3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
Apostolova, Liana G.,
Thompson, Paul M.,
Green, Amity E.,
Hwang, Kristy S.,
Zoumalan, Charleen,
Jack, Clifford R., Jr.,
Harvey, Danielle J.,
Petersen, Ronald C.,
Thal, Leon J.,
Aisen, Paul S,
Toga, Arthur W.,
Cummings, Jeffrey L.,
Decarli, Charles S.
We applied the hippocampal radial atrophy mapping technique to the baseline and follow-up magnetic resonance image data of 169 amnestic mild cognitive impairment (MCI) participants in the imaging arm of the Alzheimer’s Disease Cooperative Study MCI Donepezil/Vitamin E trial. Sixty percent of the subjects with none to mild hippocampal atrophy rated with the visual medial […]